Diasome is focused on developing novel liver hepatocyte targeting systems for injectable insulin therapies to improve the treatment of Type 1 and Type 2 diabetes. The company has developed a cell-targeted nanotechnology insulin additive designed to solve the insulin distribution problem in diabetes.

Stage: Clinical

News: Diasome Pharmaceuticals Raises $30 Million